Vitiligo: can new treatments really repigment the skin?
Vitiligo, an autoimmune disease affecting 1-2% of the population, appears as patches of depigmentation. Long considered to have 'no solution', it is now experiencing a therapeutic revolution: ruxolitinib (Opzelura), the first specific anti-JAK treatment, enables melanocytes to recolonise the skin, with on average 75% repigmentation of the face in one in two patients. But application is demanding, results are slow (6 to 24 months) and the treatment is reserved for less extensive forms. Vitiligo is neither contagious nor psychosomatic: several options exist (immunomodulators, cortisone, UVB phototherapy, melanocyte autograft), and early management is decisive.
August 1, 2026
